Updated Jul 16, 2026 · Last SEC filing 2026-05-27
SANGAMO THERAPEUTICS, INC (SGMO) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-27. 5 Form 8-K material event filings were reported by SGMO in the last 90 days. 1 Form 144 notices of proposed sale were filed for SGMO stock. InsiderAlpha tracks every SGMO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001001233 |
| Form 4 filings (90d) | 7 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-05-27 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | F — Tax withholding / forfeiture | 12.6K | $0.17 | $2K | SEC | |
| Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | F — Tax withholding / forfeiture | 4.0K | $0.17 | $703 | SEC | |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F — Tax withholding / forfeiture | 4.0K | $0.17 | $703 | SEC | |
| Jain Nikunj | Principal Accounting Officer | F — Tax withholding / forfeiture | 1.9K | $0.17 | $334 | SEC | |
| Davis Gregory D | Head of Research & Technology | F — Tax withholding / forfeiture | 1.6K | $0.17 | $284 | SEC | |
| Davis Gregory D | Head of Research & Technology | S — Open-market sale | 69.8K | $0.25 | $18K | SEC | |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | S — Open-market sale | 345.9K | $0.26 | $89K | SEC | |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F — Tax withholding / forfeiture | 12.4K | $0.47 | $6K | SEC | |
| Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | F — Tax withholding / forfeiture | 33.6K | $0.47 | $16K | SEC | |
| Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | F — Tax withholding / forfeiture | 12.4K | $0.47 | $6K | SEC | |
| Jain Nikunj | Principal Accounting Officer | F — Tax withholding / forfeiture | 5.1K | $0.47 | $2K | SEC | |
| Davis Gregory D | Head of Research & Technology | F — Tax withholding / forfeiture | 5.1K | $0.47 | $2K | SEC | |
| Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | F — Tax withholding / forfeiture | 5.3K | $0.47 | $2K | SEC | |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | F — Tax withholding / forfeiture | 2.1K | $0.47 | $975 | SEC | |
| Davis Gregory D | Head of Research & Technology | F — Tax withholding / forfeiture | 832 | $0.47 | $393 | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for SANGAMO THERAPEUTICS, INC (SGMO). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Davis Gregory D | 2 | $18K |
| Dubois-Stringfellow Nathalie | 2 | $90K |
| Willoughby Scott B. | 1 | $703 |
| Macrae Sandy | 1 | $2K |
| Jain Nikunj | 1 | $334 |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SGMO insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live SGMO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.